Relative Strength Index measures the speed and magnitude of recent price changes on a 0-to-100 scale, showing whether recent trading has leaned stronger or weaker within its range.
Relative Strength Index Analysis Today
Relative Strength Index measures the speed and magnitude of recent price changes on a 0-to-100 scale, showing whether recent trading has leaned stronger or weaker within its range. The current Relative Strength Index for Bionano Genomics is 58.47. This reading indicates consistent price behavior relative to the prior session.
On May 07 2026 Bionano Genomics was traded for 1.33 at the closing time. The top price for the day was 1.37 and the lowest listed price was 1.25 . The trading volume for the day was 234.2 K. The trading history from May 7, 2026 remained within defined bounds. The net trading delta against the current closing price is -5.26% .
Readings near the middle of the range usually indicate balanced price behavior, while higher or lower readings reflect stronger directional pressure.
These methods summarize the same price history through smoothing, range, and momentum calculations. Reviewing them alongside Relative Strength Index helps compare stable sessions with periods of wider price movement in Bionano Genomics.
Bionano Genomics's market space within the Health Care space is illustrated by the firms listed below. Key comparison metrics include price-to-earnings, profit margin, and revenue growth across Bionano Genomics' peer group. Sector-wide trends across this peer group split company-level factors from broader forces. Combining quantitative ratios with qualitative context such as management quality and market position sharpens peer comparisons.
For investors tracking Bionano Genomics, market strength indicators offer quantitative evaluation of stock behavior. When Rate of Change diverges from price direction, it often signals weakening momentum before a visible reversal in Bionano Genomics.
Analyzing Bionano Genomics' basic risk indicators provides a structured view of the risk-return trade-off for bionano genomics stock. Expected shortfall estimates the average loss in the worst-case tail scenarios, going beyond what standard deviation alone captures for Bionano Genomics.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Bionano Genomics Short Properties
Short sentiment tied to Bionano Genomics matters because heavier bearish pressure can change how quickly future price expectations become unstable. Comparing short sentiment with trend behavior, volume, and the broader market narrative provides a more grounded view.
Common Stock Shares Outstanding
5.45 million
Cash And Short Term Investments
13.26 million
More Resources for Bionano Genomics Stock Analysis
Understanding Bionano Genomics starts with reviewing its financial statements and long-term patterns. Ratios reflect how the business performs across profit and resource use.